| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | F2RL3 |
| Uniprot No | Q96RI0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-82aa |
| 氨基酸序列 | GGTQTPSVYDESGSTGGGDDSTPSILPAPRGYPGQVCANDSDTLELPDSSRALLLGWVPTRLVPA |
| 分子量 | 32.89 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人F2RL3(PAR4)蛋白研究的模拟参考文献示例(仅供格式参考，具体文献需通过学术数据库检索)：
1. **《Functional characterization of recombinant human protease-activated receptor 4 (F2RL3) in platelet activation》**
*作者：Smith A, et al.*
摘要：研究通过哺乳动物细胞系表达重组人F2RL3蛋白，揭示了其介导血小板活化的信号通路，并验证了其与凝血酶相互作用的特异性表位。
2. **《Structural insights into the activation mechanism of PAR4 receptor》**
*作者：Chen L, et al.*
摘要：利用冷冻电镜解析重组人F2RL3蛋白的活化构象，阐明了配体结合后受体构象变化对下游G蛋白偶联的调控机制。
3. **《Development of a recombinant PAR4 extracellular domain for thrombin signaling studies》**
*作者：Wang Y, et al.*
摘要：通过原核表达系统制备重组人F2RL3胞外结构域蛋白，证实其在体外实验中能够竞争性抑制凝血酶诱导的内皮细胞炎症反应。
4. **《PAR4-targeted therapeutic potential in thrombosis: Insights from recombinant protein models》**
*作者：Johnson R, et al.*
摘要：基于重组F2RL3蛋白的细胞实验和小鼠模型，评估了靶向PAR4的小分子抑制剂在抗血栓治疗中的应用前景。
**注意**：以上文献标题和内容为模拟示例，实际研究需通过PubMed、Web of Science或Google Scholar等平台检索关键词如“recombinant human F2RL3/PAR4”获取。正式引用时请确保核对作者、期刊名及年份的准确性。
Recombinant human F2RL3 protein, also known as protease-activated receptor 4 (PAR4), is a G protein-coupled receptor (GPCR) involved in cellular signaling pathways linked to hemostasis, thrombosis, and inflammation. PAR4 is activated through proteolytic cleavage by serine proteases like thrombin or trypsin, exposing a tethered ligand that triggers intracellular signaling. Unlike PAR1. which is rapidly activated by low thrombin concentrations, PAR4 responds to higher thrombin levels, enabling sustained signaling in platelets and other cells. This receptor is expressed in platelets, vascular endothelial cells, and immune cells, playing a critical role in platelet aggregation, vascular tone regulation, and inflammatory responses.
The recombinant form of F2RL3 is typically produced in mammalian or bacterial expression systems for research applications. It retains structural and functional integrity, allowing studies on PAR4-specific signaling mechanisms and its role in pathological conditions, such as cardiovascular diseases, cancer metastasis, and autoimmune disorders. Recombinant F2RL3 is essential for developing PAR4-targeted therapies, including antiplatelet drugs to prevent thrombosis while minimizing bleeding risks. Its study also aids in understanding crosstalk between coagulation pathways and inflammation, offering potential insights into therapeutic interventions for diverse diseases.
×
